Peter Birner
About
In The Last Decade
Peter Birner
166 papers receiving 8.8k citations
Hit Papers
Peers
Comparison fields: 5 of 131
- Oncology 4.0k
- Molecular Biology 3.3k
- Cancer Research 2.2k
- Pulmonary and Respiratory Medicine 2.1k
- Surgery 1.2k
Countries citing papers authored by Peter Birner
This map shows the geographic impact of Peter Birner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Birner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Birner more than expected).
Fields of papers citing papers by Peter Birner
This network shows the impact of papers produced by Peter Birner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Birner. The network helps show where Peter Birner may publish in the future.
Co-authorship network of co-authors of Peter Birner
This figure shows the co-authorship network connecting the top 25 collaborators of Peter Birner. A scholar is included among the top collaborators of Peter Birner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Birner. Peter Birner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 12 | |
| 2 | 31 | |
| 3 | 14 | |
| 4 | 52 | |
| 5 | 46 | |
| 6 | 28 | |
| 7 | Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. | 3 |
| 8 | 5 | |
| 9 | Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies. | 18 |
| 10 | 14 | |
| 11 | 30 | |
| 12 | 38 | |
| 13 | 79 | |
| 14 | 52 | |
| 15 | 80 | |
| 16 | 6 | |
| 17 | Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. | 332 |
| 18 | Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. | 111 |
| 19 | 170 | |
| 20 | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.